A Phase 1 interventional study of VR Mobility Tool in Cone-Rod Degeneration and Rod-Cone Degeneration, sponsored by National Eye Institute (NEI). Recruiting at 2 sites in 2 countries. Open to participants aged 5 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by National Eye Institute (NEI) · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Cone-Rod Dystrophies with a site in United States — 9 open to participants now, 14 under way, none of them phase 3. Cone-Rod Dystrophies · United States.
Among the 19 studies in Cone-Rod Dystrophies with a site in United States, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 1, reaches primary completion later than 12 of the 13 other live ones, and was the 10th registered.
40 studies on the registry are indexed under Cone-Rod Dystrophies; 15 are open to participants now.
Browse Cone-Rod Dystrophies studies →9 of the 19 studies in Cone-Rod Dystrophies with a site in United States are open now. Recruiting first, the newest first:
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in United States, Australia, China
Ages 18–65
BlueRock Therapeutics · Sites in United States
Ages 18+
Ascidian Therapeutics, Inc · Sites in United States
Ages 5+
Food and Drug Administration (FDA) · Sites in United States
Ages 21+
Institute of Molecular and Clinical Ophthalmology Basel · Sites in United States, China, Germany and 4 more countries
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Cone-Rod Dystrophies studies recruiting now, 10 (71%) set no upper age limit and 2 (14%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 5 Years to 120 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7
First in 2008; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 165 is above the median of 28 across 28 interventional studies indexed under Cone-Rod Dystrophies.
Median enrollment 44 across the 14 interventional studies, 100 across the 5 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 19 have an industry lead sponsor. The 10 most frequent:
National Eye Institute (NEI) is the lead sponsor of 272 studies on the registry; 17 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 8 (100%) have results posted.
National Eye Institute (NEI) has 2 studies filed under Cone-Rod Dystrophies — fewer than ten, so there is no comparison to draw.
5 of the studies in Cone-Rod Dystrophies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05294978Institute of Molecular and Clinical Ophthalmology BaselEyeConic: Qualification for Cone-Optogenetics | 2026-12 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
| NCT03011541MD Stem CellsStem Cell Ophthalmology Treatment Study II | 2027-07-31 |
| NCT06445322Ascidian Therapeutics, IncPrescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH) | 2027-08-31 |
| NCT03326336GenSight BiologicsDose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa | 2027-10-26 |
Add all 5 to your calendar (.ics) → With an account.
Among the 19 studies in Cone-Rod Dystrophies with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background:
The retina is a thin layer of tissue at the back of the eye. Retinal disease usually reduces a person s mobility because it affects how he or she moves through familiar and unfamiliar environments. Researchers want to see if a virtual reality (VR) tool can provide an easier and more accurate way to assess mobility.
Objective:
To learn if researchers can track changes in mobility in people with retinal disease using a new VR tool.
Eligibility:
People aged 5 and older with retinal disease that affects their vision, and healthy volunteers.
Design:
Participants will have 2-3 clinic visits.
Participants will wear goggles or sit in front of a screen while sitting. Using a game controller, they will navigate through 4 obstacle courses presented in VR.
Participants will have a medical history exam. They will answer questions about their family history. They will fill out questionnaires about the vision and mobility issues they have in their daily lives.
Participants will have a complete eye exam. They will read letters from a chart. Their eye pressure will be measured. Their pupils may be dilated with eye drops. Pictures of their eye will be taken. Lights will be shined in their eyes.
Participants will take a visual field test. For this, they will look into a dome and press a button when they see a light.
Participants will have an electroretinogram. For this, they will sit in the dark with their eyes patched. Then their eyes will be numbed with eye drops and they will wear contact lenses while watching flashing lights.
Participants will have optical coherence tomography. This is a noninvasive procedure. It produces cross-sectional pictures of the retina....
Objective: Designing clinical trials for advanced retinal disease represents an especially difficult challenge due to the lack of suitable outcome measures. Clinical measures such as visual field and area of atrophy measured with multimodal imaging may be highly variable and/or difficult to measure in this population. A main contributor to disability in the visually impaired is poor mobility, which is a quality of life measure used to assess visually-guided behavior in low-vision patients. The goal of our study is to determine whether parameters from a recently developed virtual reality (VR) mobility assessment tool may serve as biomarkers of functional vision in participants with advanced retinal disease. The long-term goal will be to determine whether the VR mobility assessment tool parameters can document longitudinal changes in functional vision and serve as a suitable outcome measure for clinical trials in participants with advanced retinal disease.
Study Population: Up to 120 participants with retinal disease and 45 healthy volunteers will be recruited. The upper limit of 120 participants with retinal disease was chosen to allow approximately equal groups of 60 participants with rod-cone degeneration (RCD) and 60 participants with cone-rod degeneration (CRD) to represent groups of participants with peripheral visual field constriction and central vision loss, respectively. A total of 60 per group was chosen to A) allow feasibility to be determined across age groups (e.g., 5-11 yrs., 12-50 years, over 50 years) and B) to allow for a sufficient range of disease severity to examine VR mobility test sensitivity. The number of healthy volunteers (N=45) was chosen to provide about 15 participants across each of three age groups.
Design: In this multi-site observational study, VR mobility testing will be performed in participants with retinal disease. While the ultimate goal is to use this for advanced retinal disease, in the current study we will examine participants with a wide range of retinal disease severity to enable correlations between VR mobility parameters and markers of disease severity (e.g., field size, mobility scores from questionnaires). This analysis will also help determine the range of retinal disease severity for which VR mobility will be useful. Based on the simulation studies, we predict that participants should be able to repeat the VR course between four to eight times in a one-hour session. Testing will also include best corrected visual acuity (BCVA), visual fields, optical coherence tomography (OCT), autofluorescence imaging, ultra-widefield imaging and participant reported outcome (PRO) questionnaires. Two tests of photosensitivity, Visual Photosensitivity Threshold (VPT) and Palpebral Aperture Measurement (PAM) will also be recorded in a subset of participants known to be photosensitive (e.g., albinos, achromats, and CRD), and healthy volunteers at visit 001. Participants will be required to attend two to three clinic visits within three months. VR and photosensitivity testing will be the focus of the second and third clinic visit in order to A) examine the learning effect and B) quantify test-retest variability of VR and photosensitivity test parameters.
Outcome Measures: The primary outcome is to determine whether parameters from a recently developed VR mobility tool can serve as biomarkers of functional vision in participants with retinal disease. To this end, we will examine the correlation between VR mobility test parameters (e.g., accuracy, task time) and the mobility score from a PRO questionnaire/s. A secondary outcome is to examine the correlation between the VR mobility test parameters and clinical measures of retinal structure and function (e.g., visual acuity, non-seeing area). Other secondary outcomes include quantifying the learning effect and test-retest variability of the VR test parameters, exploring the feasibility of the tool based on age and presence of physical disabilities, determining the sensitivity of VR mobility test parameters to the presence and severity of retinal disease, determining the brightest background at which participants who experience photoaversion can navigate the VR maze, and determining whether prior or present computer game playing (e.g., number of hours, type of games played, computer game platform) influences baseline performance on the VR mobility tool.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible, the following inclusion criteria must be met.
Participant must be able to read and speak English.
a. If participant is a minor, their parent or legal guardian must be able to read and speak English.
For healthy volunteers only:
EXCLUSION CRITERIA:
A participant is not eligible if any of the following exclusion criteria are present.
STUDY EYE ELIGIBILITY CRITERIA:
The participant must have at least one eye meeting all inclusion criteria.
STUDY EYE INCLUSION CRITERIA:
Healthy Volunteers Only
a. Study eye must have visual acuity of 20/20 or better, with or without correction (e.g., glasses or contact lens).
Participants with Retinal Disease Only
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with retinal disease, healthy volunteers
Diagnostic Test: VR Mobility Tool
Participant wears VR goggles and interacts with a visual avatar via a control unit to navigate four courses. Derived parameters automatically recorded by the VR system include number and type of collisions, walking speed, task time, and distance walked.
The primary outcome is to determine whether parameters from a recently developed VR mobility tool can serve as biomarkers of functional vision in participants with retinal disease
Examine the correlation between VR mobility test parameters(e.g., accuracy, task time) and the mobility score from a PRO questionnaire/s.
Time frame: Three months
Determination of the brightest background at which participants who experience photoaversion can navigate the VR maze.
Determining the brightest background at which participants who experience photoaversion can navigate the VR maze.
Time frame: Three months
Sensitivity of VR mobility test parameters to the presence and severity of retinal disease.
Determining the sensitivity of VR mobility test parameters to the presence and severity of retinal disease.
Time frame: Three Months
Learning effect on and test-retest variability of the VR test parameters.
Quantifying the learning effect on and testretest variability of the VR test parameters.
Time frame: Three Months
Effect of prior game play
Determining whether prior or present computer game playing (e.g., number of hours, type of games played, computer game platform) influences baseline performance on the VR mobility tool.
Time frame: Three Months
Feasibility of the tool
Determining the feasibility of the tool based on age and presence of physical disabilities.
Time frame: Three Months
Correlation between the VR mobility test parameters and clinical measures of retinal structure and function (e.g., visual acuity, non-seeing area)
Determining the correlation between VR mobility test parameters and clinical measures of retinal structure and function.
Time frame: Three Months
Plan to share: Undecided
Started Jul 2023 (actual). Primary completion is estimated for Dec 2030, 89 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Eye Institute (NEI) →